tag legend-biotech 
pharmaphorum
AUGUST 25, 2022
It joins a number of other BCMA-directed therapies for multiple myeloma, including GSK’s first-to-market antibody-drug conjugate Blenrep (belantamab mafodotin), Bristol-Myers Squibb/bluebird bio’s CAR-T therapy Abecma (idecabtagene vicleucel) and J&J/Legend Biotech’s CAR-T Carvykti (ciltacabtagene autoleucel).
pharmaphorum
MARCH 27, 2022
Carvykti – developed by J&J with China’s Legend Biotech – was approved on the back of a single arm, open-label, clinical trial in 113 patients – CARTITUDE-1 – which showed an overall response rate of 84%, with signs of the cancer disappearing altogether in 69% of recipients.
pharmaphorum
FEBRUARY 26, 2021
2017 saw J&J make its biggest ever acquisition deal after fighting off competition from Sanofi to acquire Swiss biotech Actelion for $30 billion. The company has many interesting drugs in its pipeline, including a CAR-T therapy developed in partnership with Legend Biotech.
Expert insights. Personalized for you.
98 
Let's personalize your content